Parkinson's Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds

The Parkinson's Disease (PD) market was valued at approximately USD 3.5 billion in 2025 and is projected to grow at a robust CAGR during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Parkinson's disease landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Parkinson's Disease market is increasingly guided by disease-modifying and symptomatic treatment strategies. Levodopa-based therapies continue to represent a significant portion of the market, with novel infusion technologies like VYALEV representing a major advancement. Currently, established therapies generate substantial annual sales, with novel dopamine receptor agonists and emerging therapeutics poised to reshape the treatment landscape.

DelveInsight's report, "Parkinson's Disease Market Insights, Epidemiology, and Market Forecast- 2034," provides a comprehensive analysis of the Parkinson's disease landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Parkinson's disease market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Parkinson's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, visit Parkinson's Disease Market Forecast

Some of the key facts of the Parkinson's Disease Market Report:

• Key Parkinson's Disease Companies: AbbVie, Supernus Pharmaceuticals, Biogen, Cerevel Therapeutics, Kissei Pharmaceutical, Prothena Corporation, Roche, Neurocrine Biosciences, Voyager Therapeutics, and others.
• Key Parkinson's Disease Therapies: VYALEV (foscarbidopa and foslevodopa), Onapgo (apomorphine hydrochloride), Tavapadon, BIIB122, XADAGO (safinamide), DUOPA/DUODOPA (levodopa-carbidopa infusion), INBRIJA (levodopa inhalation powder), ONGENTYS (opicapone), Prasinezumab, AAV2-GDNF, Ambroxol, CVN-424, Glovadalen, and others.
• The Parkinson's disease market is expected to surge due to the disease's increasing prevalence, especially in aging populations, and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson's disease pipeline products will significantly revolutionize the Parkinson's disease market dynamics.

Parkinson's Disease Overview

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra region of the brain. It is the second most common neurodegenerative disease globally after Alzheimer's disease. The condition manifests through motor symptoms, including resting tremor, bradykinesia (slowness of movement), muscle rigidity, and postural instability. Non-motor symptoms such as cognitive decline, mood disorders, sleep disturbances, and autonomic dysfunction also significantly impact patient’s quality of life. Parkinson's disease is primarily diagnosed in older adults, though early-onset Parkinson's disease can occur in younger populations. The pathophysiology involves the accumulation of alpha-synuclein protein, leading to neurodegeneration and progressive motor and non-motor manifestations. Risk factors include advanced age, family history, environmental exposures, and genetic factors such as LRRK2 mutations.

Key Trends in Parkinson's Disease Therapeutics Market:

• Rising Adoption of Infusion-Based Therapies: Increasing use of subcutaneous and continuous infusion therapies such as VYALEV and Onapgo for advanced Parkinson's disease management.
• Disease-Modifying Approaches: Growing focus on neuroprotective and disease-modifying therapies targeting alpha-synuclein and neuroinflammation pathways.
• Precision Medicine & Biomarker Testing: Enhanced molecular diagnostics and biomarker identification enabling personalized treatment strategies for genetically defined patient populations.
• Novel Dopamine Receptor Agonists: Development of next-generation dopamine D1/D5 receptor agonists like tavapadon offering once-daily oral dosing.
• Gene Therapy Innovation: Advanced gene therapy approaches including AAV2-based therapies targeting GBA1 and GDNF delivery.
• Digital Health Integration: Use of remote patient monitoring, wearable devices, and AI-driven diagnostics to optimize treatment and enhance patient outcomes.

Parkinson's Disease Epidemiology

The Parkinson's disease epidemiology segment of the report provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on key genetic subtypes such as LRRK2 mutations and GBA1 variants. The report also highlights risk factors, disease burden, projections for future trends, and the increasing prevalence in aging populations, helping stakeholders understand the scope of Parkinson's disease and plan targeted interventions, research, and treatment strategies.

Parkinson's Disease Epidemiology Segmentation:

The Parkinson's Disease market report proffers epidemiological analysis for the study period 2025–2034 in the 7MM segmented into:

• Total Parkinson's Disease Diagnosed Prevalent Cases
• Parkinson's Disease Age-specific Diagnosed Prevalent Cases
• Parkinson's Disease Stage-specific Diagnosed Prevalent Cases
• Parkinson's Disease Gender-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Parkinson's disease epidemiology trends @ Parkinson's Disease Epidemiology Forecast

Recent Developments In The Parkinson's Disease Treatment Landscape:

• In September 2025, AbbVie announced the submission of a New Drug Application (NDA) to the FDA for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist. The submission marks a significant milestone for a potential first-in-class once-daily oral treatment option for Parkinson's disease. The NDA submission is based on compelling results from the TEMPO clinical development program, which evaluated the efficacy, safety, and tolerability of tavapadon across a broad Parkinson's disease population. This includes two Phase 3 trials (TEMPO-1 and TEMPO-2) in early Parkinson's disease and one Phase 3 trial (TEMPO-3) evaluating tavapadon as adjunctive therapy to levodopa in patients experiencing motor fluctuations. If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease therapeutics.
• In September 2025, Novartis signed global license deal with Arrowhead Pharmaceuticals for ARO-SNCA, a preclinical siRNA therapy targeting alpha-synuclein in Parkinson's Disease.
• In October 2025, EJS ACT-PD, the largest-ever Parkinson's trial, launched in the UK to test disease-modifying treatments like telmisartan and terazosin in Phase III.​
• In November 2025, BlueRock Therapeutics published positive 36-month data from Phase I bemdaneprocel trial, confirming safety and efficacy signals.
• In February 2025, Supernus Pharmaceuticals announced FDA approval of Onapgo (apomorphine hydrochloride), the first subcutaneous apomorphine continuous infusion therapy approved in the United States for Parkinson's disease. The therapy is designed to provide continuous 24-hour dopaminergic stimulation, reducing off-time periods and motor fluctuations in advanced Parkinson's disease patients.
• In October 2024, AbbVie announced FDA approval of VYALEV (foscarbidopa and foslevodopa), marking a significant milestone as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor fluctuations in adults with advanced Parkinson's disease.

Parkinson's Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Parkinson's disease market or expected to get launched during the study period. The analysis covers Parkinson's disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers Parkinson's disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Parkinson's Disease Therapies and Key Companies

• VYALEV (foscarbidopa and foslevodopa): AbbVie
• Onapgo (apomorphine hydrochloride): Supernus Pharmaceuticals
• Tavapadon: Cerevel Therapeutics (AbbVie partnership)
• BIIB122 (DNL151): Biogen
• Prasinezumab: Prothena Corporation/Roche
• GBA1 Gene Therapy: Neurocrine Biosciences/Voyager Therapeutics
• XADAGO (safinamide): Newron Pharmaceuticals
• DUOPA/DUODOPA (levodopa-carbidopa infusion): AbbVie
• INBRIJA (levodopa inhalation powder): Acorda Therapeutics
• ONGENTYS (opicapone): Bial
• CVN-424 (GPCR6 inverse agonist): Cerevel Therapeutics

To know more about Parkinson's disease companies working in the treatment market, visit @ Parkinson's Disease Clinical Trials and Therapeutic Assessment

Parkinson's Disease Market Drivers

• Increasing prevalence of Parkinson's disease globally, particularly in aging populations, driving demand for effective and innovative therapies
• Growing unmet medical need for disease-modifying therapies that can slow or halt disease progression
• Advancements in molecular diagnostics and biomarker identification enabling precision medicine approaches for genetically defined patient populations
• Rising healthcare expenditure and government initiatives supporting neurodegenerative disease research and patient care
• Expanding awareness and improved early diagnosis through enhanced screening programs and patient education
• Development of next-generation therapies including infusion-based treatments, gene therapies, and cell-based interventions improving patient outcomes
• Increasing clinical trial activity and regulatory support for novel therapeutic approaches

Parkinson's Disease Market Barriers

• High cost of innovative therapies and infusion-based treatments limiting patient access and affordability
• Complex clinical trial designs and lengthy regulatory approval processes extending time-to-market for new therapies
• Development challenges in addressing non-motor symptoms and cognitive complications
• Limited awareness and accessibility of advanced treatments in emerging markets
• Side effects and safety concerns associated with long-term dopaminergic therapies
• Patient heterogeneity and variability in treatment response due to genetic and environmental factors
• Potential for treatment resistance and disease progression despite optimal therapy

Scope of the Parkinson's Disease Market Report

• Study Period: 2025–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Parkinson's Disease Companies: AbbVie, Supernus Pharmaceuticals, Biogen, Cerevel Therapeutics, Kissei Pharmaceutical, Prothena Corporation, Roche, Neurocrine Biosciences, Voyager Therapeutics, Acorda Therapeutics, Newron Pharmaceuticals, Bial, and others
• Key Parkinson's Disease Therapies: VYALEV (foscarbidopa and foslevodopa), Onapgo (apomorphine hydrochloride), Tavapadon, BIIB122, XADAGO (safinamide), DUOPA/DUODOPA (levodopa-carbidopa infusion), INBRIJA (levodopa inhalation powder), ONGENTYS (opicapone), Prasinezumab, AAV2-GDNF, Ambroxol, CVN-424, Glovadalen, and others
• Parkinson's Disease Therapeutic Assessment: Parkinson's disease current marketed and Parkinson's disease emerging therapies
• Parkinson's Disease Market Dynamics: Parkinson's disease market drivers and Parkinson's disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Parkinson's Disease Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Market Access and Reimbursement

Discover more about therapies set to grab major Parkinson's disease market share @ Parkinson's Disease Treatment Market